Press Releases

 Jan 05, 2023, 07:30 ET  15.4% increase in net product revenue over the prior quarter 1,290% increase over the comparable quarter in 2021 11.5% increase in prescriptions dispensed over the prior quarter Increased 134% over the comparable quarter in 2021 CRANBURY, N.J., January 5, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical […]

 Nov 14, 2022, 07:30 ET  Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Size of 350 patients Topline Results Currently Expected Second Quarter Calendar 2023 Vyleesi® – Net Product Revenue Increased 13% and Prescriptions Dispensed Increased 17%, Over the Prior Quarter Prescription Refills Exceed 50%

 Nov 09, 2022, 17:16 ET  CRANBURY, N.J., Nov. 9, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2023 operating results on Monday, November 14, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive

 Oct 31, 2022, 09:30 ET  CRANBURY, N.J., Oct. 31, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and

 Oct 24, 2022, 17:32 ET  Preclinical data shows efficacy in animal models of ulcerative colitis Human pharmacokinetic data show oral formulation releases PL8177 in colon CRANBURY, N.J., Oct. 24, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor

 Oct 20, 2022, 07:30 ET  Oral PL8177 may provide an effective, safe, and tolerable treatment option for ulcerative colitis patients prior to being treated with immunosuppressive therapies, which have significant safety and tolerability concerns Primary endpoint is the Mayo Endoscopic Subscore, which evaluates the level of disease in the colon mucosa Interim data currently expected

 Oct 17, 2022, 07:30 ET  Peer-reviewed paper presents notable mechanism of action findings Bremelanotide significantly increased sexual desire for up to 24 hours post administration CRANBURY, NJ, Oct. 17, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor

 Oct 13, 2022, 07:30 ET  Net product revenue for prescriptions dispensed increased 20% Prescriptions dispensed increased 17%, over prior quarter Refills accounted for over 50% of prescriptions dispensed CRANBURY, N.J., Oct. 13, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of

 Sep 29, 2022, 15:45 ET  Overview of Development Pipeline of Melanocortins for Treatment of Ocular Conditions and Role in Resolving Inflammation PL9643 Phase 3 Study Results in Dry Eye Disease Currently Expected 2Q 2023 Palatin Progressing Development Programs in Retinal and Front-of-the-Eye Indications Supported by Breakthrough Science CRANBURY, N.J., Sept. 29, 2022 /PRNewswire/ — Palatin

 Sep 29, 2022, 13:31 ET  CRANBURY, N.J., Sept. 29, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that the Company will participate in the Ladenburg Thalmann Healthcare Conference on September 29, 2022. Carl Spana,